U.S. Markets Allogene Therapeutics Highlights Promising Phase 1 | U.S. Markets byMarketWire Editorial TeamJune 1, 2025
U.S. Markets Actuate Therapeutics Reports Positive Phase 2 | U.S. Markets byMarketWire Editorial TeamMay 31, 2025
U.S. Markets Relmada Therapeutics Presents NDV-01 Data at | U.S. Markets byMarketWire Editorial TeamApril 27, 2025
U.S. Markets Mineralys Therapeutics Announces Pricing of $175 | U.S. Markets byMarketWire Editorial TeamMarch 12, 2025
Global Markets TG Therapeutics soared 17% after earnings surprise | Global Market News byMarketWire Editorial TeamMarch 3, 2025
Global Markets Prediction: CRISPR Therapeutics Will Beat the | Global Market News byMarketWire Editorial TeamMarch 1, 2025
